BR112021024925A2 - Método para a definição de uma vacina personalizada contra o hiv/aids - Google Patents

Método para a definição de uma vacina personalizada contra o hiv/aids

Info

Publication number
BR112021024925A2
BR112021024925A2 BR112021024925A BR112021024925A BR112021024925A2 BR 112021024925 A2 BR112021024925 A2 BR 112021024925A2 BR 112021024925 A BR112021024925 A BR 112021024925A BR 112021024925 A BR112021024925 A BR 112021024925A BR 112021024925 A2 BR112021024925 A2 BR 112021024925A2
Authority
BR
Brazil
Prior art keywords
individual
hiv
peptides
vaccine
aids
Prior art date
Application number
BR112021024925A
Other languages
English (en)
Inventor
Andrea Savarino
Luca Shytaj Iart
Sobhie Diaz Ricardo
Original Assignee
Andrea Savarino
Daniele Luna Da Cunha
Luca Shytaj Iart
Sobhie Diaz Ricardo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Andrea Savarino, Daniele Luna Da Cunha, Luca Shytaj Iart, Sobhie Diaz Ricardo filed Critical Andrea Savarino
Publication of BR112021024925A2 publication Critical patent/BR112021024925A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4634—Antigenic peptides; polypeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

método para a definição de uma vacina personalizada contra o hiv/aids. uma nova abordagem para o desenvolvimento de uma vacina personalizada. esta abordagem é baseada em: a) sequenciamento do gene gag de um indivíduo infectado pelo hiv tratado com terapia anti-retroviral; b) sequenciação dos alelos hla do mesmo indivíduo; c) seleção dos epítopos reconhecidos pelo hla classe i do indivíduo nas seqüências de aminoácidos gag256-377, gag147-169 e / ou gag225-251 altamente conservadas. um algoritmo original que projeta o peptídeo alvo para a vacina a partir de sequências virais e hla de um indivíduo com hiv/aids, forma o núcleo da presente invenção. o algoritmo original faz uso extensivo do software de código aberto existente para o design de proteínas. os péptidos concebidos desta maneira e consequentemente sintetizados podem ser explorados como uma vacina terapêutica contra o hiv/aids. os veículos para esses peptídeos podem ser células dendríticas de um indivíduo pulsadas com a combinação de peptídeos ou um vetor viral ou de dna específico, levando à expressão intracelular dos peptídeos virais. a presente abordagem de vacina pode contribuir para o controle da viremia uma vez suspensas as terapias anti-retrovirais.
BR112021024925A 2019-06-10 2020-06-10 Método para a definição de uma vacina personalizada contra o hiv/aids BR112021024925A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962859286P 2019-06-10 2019-06-10
PCT/BR2020/050204 WO2020248032A1 (pt) 2019-06-10 2020-06-10 Método para a definição de uma vacina personalizada contra o hiv/aids

Publications (1)

Publication Number Publication Date
BR112021024925A2 true BR112021024925A2 (pt) 2022-01-18

Family

ID=73781138

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021024925A BR112021024925A2 (pt) 2019-06-10 2020-06-10 Método para a definição de uma vacina personalizada contra o hiv/aids

Country Status (4)

Country Link
US (1) US20220111036A1 (pt)
BR (1) BR112021024925A2 (pt)
WO (1) WO2020248032A1 (pt)
ZA (1) ZA202110613B (pt)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020182222A1 (en) * 1998-07-10 2002-12-05 Groot Anne De HIV vaccine candidate peptides
US20020172688A1 (en) * 2001-03-16 2002-11-21 Bruce Lyday HLA-restricted cytotoxic T-Lymphocytevaccine for prevention of HIV infection
ITRM20030386A1 (it) * 2003-08-05 2005-02-06 Istituto Naz Per Le Malattie Infettive Lazz Metodo e test diagnostici basati sull'analisi citofluorimetrica dei linfociti t antigene-specifici.
EP1794327B1 (en) * 2004-09-14 2016-11-30 Argos Therapeutics, Inc. Strain independent amplification of pathogens and vaccines thereto
FR2882557A1 (fr) * 2005-02-25 2006-09-01 Centre Nat Rech Scient Epitopes de vih et composition pharmaceutique les contenant
AU2006283101B2 (en) * 2005-08-23 2013-03-07 Beth Israel Deaconess Medical Center Polyvalent vaccine
BRPI0504117A (pt) * 2005-09-05 2007-05-22 Fundacao De Amparo A Pesquisa epìtopos, combinação de epìtopos, usos de epìtopos ou sua combinação, composição, usos da composição, vacinas profiláticas anti-hiv-1, vacinas terapêuticas, método para a identificação de epìtopos e métodos para o tratamento ou prevenção
EP2745845A1 (en) * 2012-12-19 2014-06-25 Centre Hospitalier Universitaire de Bordeaux A method for preventing or treating an HIV infection

Also Published As

Publication number Publication date
US20220111036A1 (en) 2022-04-14
WO2020248032A1 (pt) 2020-12-17
ZA202110613B (en) 2023-06-28

Similar Documents

Publication Publication Date Title
Ortega et al. Unrevealing sequence and structural features of novel coronavirus using in silico approaches: The main protease as molecular target
Smith et al. IFITM proteins—cellular inhibitors of viral entry
Te Velthuis et al. Influenza virus RNA polymerase: insights into the mechanisms of viral RNA synthesis
Fechter et al. Recognition of mRNA cap structures by viral and cellular proteins
Hou et al. Pig has no uncoupling protein 1
Kanai et al. TAZ: a novel transcriptional co‐activator regulated by interactions with 14‐3‐3 and PDZ domain proteins
McNab et al. Tripartite-motif proteins and innate immune regulation
Kemler Classical cadherins
Wang et al. Viperin inhibits hepatitis C virus replication by interfering with binding of NS5A to host protein hVAP-33
Stanley et al. Structural insight into the human immunodeficiency virus Vif SOCS box and its role in human E3 ubiquitin ligase assembly
Kasahara et al. Characterization of homo-and heterodimerization of cardiac Csx/Nkx2. 5 homeoprotein
Yang et al. RING domain is essential for the antiviral activity of TRIM25 from orange spotted grouper
Yángüez et al. So similar, yet so different: selective translation of capped and polyadenylated viral mRNAs in the influenza virus infected cell
Chang et al. Tripartite motif (TRIM) 12c, a mouse homolog of TRIM5, is a ubiquitin ligase that stimulates type I IFN and NF-κB pathways along with TNFR-associated factor 6
Postika et al. Boundaries mediate long-distance interactions between enhancers and promoters in the Drosophila Bithorax complex
Wang et al. Expression of long noncoding RNA LIPCAR promotes cell proliferation, cell migration, and change in phenotype of vascular smooth muscle cells
Lin et al. Nullbasic, a potent anti-HIV tat mutant, induces CRM1-dependent disruption of HIV rev trafficking
Chen et al. Duck stimulator of interferon genes plays an important role in host anti-duck plague virus infection through an IFN-dependent signalling pathway
Goossens et al. Characterisation of chicken ZAP
Kwak et al. Self-association of the Lentivirus protein, Nef
Hu et al. Immunoglobulin mimicry by Hepatitis C Virus envelope protein E2
BR112021024925A2 (pt) Método para a definição de uma vacina personalizada contra o hiv/aids
Cossins et al. Precise prediction of a Kk-restricted cytotoxic T cell epitope in the NS1 protein of influenza virus using an MHC allele-specific motif
Macleod et al. Mapping of the interaction domains of the Crimean–Congo hemorrhagic fever virus nucleocapsid protein
Blaine et al. Duck TRIM27-L enhances MAVS signaling and is absent in chickens and turkeys